Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Nilotinib is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations. Nilotinib is a moderate inhibitor of CYP3A4 and in vitro data indicate that it inhibits UGT1A1.Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9, but it is unlikely to be affected by nilotinib as coadministration with the strong UGT1A1 inhibitor atazanavir was predicted to increase oral cabotegravir (30 mg once daily) exposure by 11% which is considered to be not clinically relevant. Similarly, a non-relevant effect is expected with intramuscular cabotegravir. Nilotinib could increase rilpivirine exposure although to a limited extent. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with nilotinib. However, the product label for rilpivirine indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Nilotinib has a possible risk of QTc prolongation and/or TdP on the CredibleMeds.org website. An interaction to increase QTc prolongation is unlikely to occur with nilotinib.